I-Mab (NASDAQ: IMAB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel biologics directed at cancer and autoimmune diseases. Since its founding in 2016, the company has built a diverse pipeline of monoclonal antibodies and bispecific antibody candidates that target key immune checkpoints and cytokine pathways. I-Mab’s approach combines deep expertise in immunology with advanced engineering capabilities to create therapies designed to enhance anti-tumor immunity and modulate inflammatory responses.
The company’s lead programs include a CD47 checkpoint inhibitor, an IL-6 receptor antagonist and several proprietary monoclonal antibodies directed at targets such as CD73, T-cell checkpoints and B-cell maturation antigens. Several of these candidates have advanced into multiple Phase 2 and Phase 3 clinical trials across hematological malignancies, solid tumors and autoimmune indications. I-Mab has also established strategic partnerships with global biopharma companies to co-develop and commercialize selected assets, leveraging its internal R&D platform alongside external regulatory and commercial expertise.
I-Mab operates research and development centers in Shanghai and Suzhou, China, as well as a U.S. subsidiary in New Jersey. This transcontinental footprint supports a robust global clinical trial network spanning Asia, North America and Europe. The company’s manufacturing strategy includes collaborations with contract development and manufacturing organizations (CDMOs) to ensure scalable supply of clinical and commercial products, while its regulatory teams engage with health authorities across major markets to drive accelerated development pathways.
Under the leadership of Chief Executive Officer Jonathan Lim and Chairman Peiying Zhang, I-Mab has grown from a virtual startup into a multi-disciplinary organization with experts in drug discovery, translational research, clinical development and regulatory affairs. The senior management team and scientific advisory board comprise industry veterans and academic thought leaders, reflecting I-Mab’s commitment to innovation and evidence-driven development. As the company progresses its most advanced candidates toward regulatory submission, it continues to expand its platform capabilities and explore new targets in oncology and immunology.
AI Generated. May Contain Errors.
